Diagnosis and treatment of functional gastrointestinal disorders in the Asia-Pacific region: A survey of current practices

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 3, 2011, Pages 2-11

  Miura, Soichiro ^a   Sugano, Kentaro ^b   Kinoshita, Yoshikazu ^c   Fock, Kwong Ming ^d   Goh, Khean Lee ^e   Gibson, Peter ^f  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF MALAYA   (Malaysia)

^f MONASH UNIVERSITY   (Australia)

Author keywords

Asia Pacific region; Diagnosis; Functional dyspepsia; Irritable bowel syndrome; Questionnaire; Treatment

Indexed keywords

ANTIDIARRHEAL AGENT; HERBACEOUS AGENT; LAXATIVE; PROKINETIC AGENT;

ARTICLE; ASIA; BLOOD EXAMINATION; DIAGNOSTIC PROCEDURE; DIET; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DIGESTIVE TRACT ENDOSCOPY; DYSPEPSIA; ERADICATION THERAPY; FUNCTIONAL DYSPEPSIA; GENERAL PRACTITIONER; HEALTH SERVICE; HELICOBACTER PYLORI; HERBAL MEDICINE; HUMAN; IRRITABLE COLON; JAPAN; LIFESTYLE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; PSYCHOTHERAPY; QUESTIONNAIRE;

EID: 79953104164     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06635.x     Document Type: Article

References (31)

1. Öhman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat. Rev. Gastroenterol. Hepatol. 2010; 7: 163-73.
2. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
3. Tack J, Talley NJ, Camilleri M etal. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79.
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
5. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. 2): II37-42.
6. Sasaki D, Matsueda K. BMW (Bowel Motility Workshop) club symposium: Japanese guideline for the management of irritable bowel syndrome. Ther. Res. 2000; 21: 1741-60. (in Japanese).
7. Asaka M, Kato M, Takahashi S etal. Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20.
8. Leung WK, Wu MS, Kakugawa Y etal. Screening of gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008; 9: 279-87.
9. Fock KM, Katelaris P, Sugano K etal. Asia-Pacific Conference. Second Asia-pacific Consensus Guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009; 24: 1587-600.
10. Gibson PR. Overview of inflammatory bowel disease in Australia in the last 50years. J. Gastroenterol. Hepatol. 2009; 24 (Suppl. 3): S63-8.
11. Cummins AG, Roberts-Thomson IC. Prevalence of celiac disease in the Asia-Pacific region. J. Gastroenterol. Hepatol. 2009; 24: 1347-51.
12. Li X, Chen H, Lu H etal. The study on the role of inflammatory cells and mediators in post-infectious functional dyspepsia. Scand. J. Gastroenterol. 2010; 45: 573-81.
13. Tack J, Caenepeel P, Arts J etal. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut 2005; 54: 1370-76.
14. Nakajima S, Takahashi K, Sato J etal. Spectra of functional gastrointestinal disorders diagnosed by Rome III integrative questionnaire in a Japanese ourtpatient office and the impact of overlapping. J. Gastroenterol. Hepatol. 2010; 25 (Suppl. 1): S138-43.
15. Gwee KA, Bak YT, Ghoshal U etal. Asian consensus on irritable bowel syndrome. J. Gastroenterol. Hepatol. 2010; 25: 1189-205.
16. Shindo T, Futagami S, Hiratsuka T etal. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion 2009; 79: 65-72.
17. Wang WH, Huang JQ, Zheng GF etal. Effects of proton-pump inihibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin. Gastroenterol. Hepatol. 2007; 5: 178-85.
18. Xiao YL, Peng S, Tao J etal. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am. J. Gastroenterol. 2010; 105: 2626-31.
19. Wong WM, Wong BC, Hung WK etal. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002; 51: 502-6.
20. Hiyama T, Yoshihara M, Matsuo K etal. Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J. Gastroenterol. Hepatol. 2007; 22: 1566-70.
21. Otaka M, Jin M, Odashima M etal. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment. Pharmacol. Ther. 2005; 21 (Suppl. 2): 42-6.
22. Hsu YC, Liou JM, Yang TH etal. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? J. Gastroenetrol. 2010; 45. DOI: 10.1007/s00535-010-0334-1. (Eup ahead of print).
23. Khan S, Chang L. Diagnosis and management of IBS. Nat. Rev. Gastroenterol. Hepatol. 2010; 7: 565-81.
24. Matsueda K, Harasawa S, Hongo M etal. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetoron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand. J. Gastroenterol. 2003; 43: 1202-11.
25. Suzuki H, Inadomi JM, Hibi T. Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol. Motil. 2009; 21: 688-96.
26. Hojo M, Miwa H, Yokoyama T etal. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J. Gastroenterol. 2005; 40: 1036-44.
27. Miwa H, Nagahara A, Tominaga K etal. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am. J. Gastroenterol. 2009; 104: 2779-87.
28. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Eit N. Bulking agents, antispasmodic and anti-depressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 2005; 18: CD003460.
29. Ford AC, Talley NJ, Schoen Feld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
30. Hamilton J, Guthrie E, Creed F etal. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000; 119: 661-9.
31. Lackner JM, Jaccard J, Krasner SS etal. How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. Gastroenterology 2007; 133: 433-44.